

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Annual General Meeting.

The board of directors (the “**Board**”) of VIVA BIOTECH HOLDINGS (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at Meeting Room A615, 735 Ziping Road, Zhoupu Town, Pudong New District, Shanghai, PRC on Friday, June 26, 2026 at 10:00 a.m..

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) dated April 23, 2026. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2025.	887,080,481 (99.93%)	625,000 (0.07%)
2.	(a) To re-elect Mr. Ren Delin as executive director of the Company;	987,694,481 (99.99%)	11,000 (0.01%)
	(b) To re-elect Mr. Wu Yuting as non-executive director of the Company;	987,694,481 (99.99%)	11,000 (0.01%)
	(c) To re-elect Mr. Fu Lei as independent non-executive director of the Company;	987,694,481 (99.99%)	11,000 (0.01%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	To authorise the board of directors of the Company to fix the remuneration of all the directors.	887,694,481 (99.99%)	11,000 (0.01%)
4.	To re-appoint Ernst & Young as auditor of the Company and authorise the board of directors of the Company to fix their remuneration.	887,694,481 (99.99%)	11,000 (0.01%)
5.	(A) To give a general mandate to the directors of the Company to allot, issue or deal with additional shares (including any sale or transfer of treasury shares out of the treasury that are held as treasury shares of the Company) not exceeding 20% of the issued share capital of the Company as at the date of this resolution (excluding any treasury shares).	867,225,768 (97.69%)	20,479,713 (2.31%)
	(B) To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company as at the date of this resolution (excluding any treasury shares).	887,694,481 (99.99%)	11,000 (0.01%)
	(C) To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue shares (including any sale or transfer of treasury shares out of the treasury that are held as treasury shares of the Company) by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 5(B).	867,225,768 (97.69%)	20,479,713 (2.31%)

As more than 50% of the votes were cast in favour of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

The total number of issued Shares as at the date of the Annual General Meeting was 2,104,564,853 (including 9,485,500 repurchased shares of the Company pending cancellation). The total number of shares of the Company entitling the Shareholders to attend and vote for or against all resolutions at the Annual General Meeting was 2,095,079,353 shares (9,485,500 repurchased shares of the Company pending cancellation which have no voting rights and are not included in the total number of shares of the Company entitling the Shareholders to attend and vote at the Annual General Meeting). There were no Shares entitling the holders to attend and abstain from voting in favour at the Annual General Meeting as set out in rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting. No person was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting and no party has stated its intention in the Circular to vote against or to abstain from voting the resolutions proposed at the Annual General Meeting.

Tricor Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, was appointed as the scrutineer for the vote-taking at the Annual General Meeting. The Executive Directors, Mr. Mao Chen Cheney, Mr. Wu Ying and Mr. Ren Delin, the Non-executive Director, Mr. Wu Yuting and the Independent Non-executive Directors, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang attended and participated in the Annual General Meeting either in-person or by electronic means.

By order of the Board
VIVA BIOTECH HOLDINGS
Mao Chen Cheney
Chairman and Executive Director

Hong Kong, June 26, 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director, namely, Mr. WU Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.